胃泌素抑制肽(GIP)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit DIY Materials for Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 編號KSA882Hu11
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 試劑內(nèi)容包被抗體、生物素標(biāo)記的競爭物、標(biāo)準(zhǔn)品、HRP標(biāo)記的鏈霉親和素、TMB底物、96孔板
- 可檢測樣本Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
- 可適用原理競爭抑制酶聯(lián)免疫吸附試驗(yàn)法測抗原
- 可檢測范圍61.7-5000pg/mL
- 可適靈敏度23.9pg/mL
- 應(yīng)用Main materials for "Do It (ELISA Kit) Yourself".
- 下載英文說明書 中文說明書
- 規(guī)格96T*596T*1096T*2096T*5096T*100
- 價(jià)格¥ 6804¥ 11340¥ 20412¥ 39690¥ 68040
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
試劑盒中的抗體對胃泌素抑制肽(GIP)具有高靈敏度和高特異性，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
用法
1.用100μL每孔的工作濃度的包被抗體包被96孔板，4度孵育過夜或者37度孵育2小時(shí)；
2.洗板1次；
3.用200μL每孔的工作濃度的封閉液,37度孵育1.5小時(shí)；
4.洗板1次。酶標(biāo)板即可用于ELISA實(shí)驗(yàn)，后續(xù)使用方法與ELISA同。
儲存
抗體，標(biāo)準(zhǔn)品和HRP標(biāo)記的鏈霉親和素在-20度保存，TMB需在4度保存，96孔板在室溫保存。所有組分保質(zhì)期為1年，試劑一旦開封，在4度保存時(shí)間為1個(gè)月。
配套試劑
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA882Hu01 | 胃泌素抑制肽(GIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA882Hu11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| CPA882Hu21 | 胃泌素抑制肽(GIP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAA882Hu08 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA882Hu01 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA882Hu21 | 胃泌素抑制肽(GIP)單克隆抗體 | IHC |
| MAA882Hu22 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC |
| MAA882Hu23 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
| CEA882Hu | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA882Hu | 胃泌素抑制肽(GIP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA882Hu11 | 胃泌素抑制肽(GIP)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Scientific Reports | The?anti-hyperglycemic?efficacy?of a?lipid-lowering?drug?Daming?capsule?and the?underlyingsignaling?mechanisms?in a?rat?model?of?diabetes?mellitus.[pubmed:27721485] |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats.[pubmed:28840471] |
| Obesity?Surgery? | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague?…[Pubmed:29098544] |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity[] |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients[Pubmed: 31734225] |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats[Pubmed: 31701411] |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes[Pubmed:35251693] |